ReviewFrontiers in cardiovascular medicine2026
MIAT: An important long non-coding RNA regulating cardiovascular and cerebrovascular diseases.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular and cerebrovascular diseases remain the leading cause of death worldwide. Myocardial infarction-associated transcript (MIAT), a type of long non-coding RNA, has been reported to exert regulatory functions across multiple diseases in studies, and may serve as a promising therapeutic candidate in certain pathological conditions. This review provides a comprehensive analysis of the basic characteristics of MIAT, the latest research advancements, its involvement in cardiovascular and cerebrovascular diseases, and its potential as a biomarker and therapeutic target. The objective is to summarize the current understanding and mechanisms of MIAT, offering further scientific evidence to support its role in the treatment of cardiovascular and cerebrovascular diseases associated with MIAT. Additionally, this review explores the challenges and practical considerations for the clinical application of MIAT, aiming to provide new perspectives on its clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.